



European Monitoring Centre
for Drugs and Drug Addiction

PROGRAMME

Drug-related infectious diseases (DRID) Annual expert meeting

15–16 June 2015
EMCDDA, Lisbon

Drug-related infectious diseases (DRID)

More information, presentations, supporting documents and updates are available on <http://www.emcdda.europa.eu/expert-meetings/2015/drd-drid>

Monday, 15 June 2015			
08.45	Arrival of participants at Conference Centre		
09.15	<p>Plenary session 1 Aims and objectives, summary of latest data from national abstracts, rapid updates Chair: Isabelle Giraudon and Elena Alvarez</p> <p>The purpose of this session is to present the aims of the event and to share up-to-date information (2014/15) about the DRID situation and responses in Europe, from the network and international organisations</p> <p>Presentation of the objectives and expectations — Isabelle Giraudon and Julian Vicente, EMCDDA Most recent data, analyses and feedback from the 2015 'national abstracts' — Eleni Kalamara EMCDDA</p> <p>Rapid updates</p> <ul style="list-style-type: none"> • Experimentation of drug consumption rooms in France. Anne-Claire Brisacier, France • Increase in injecting cocaine use and a parallel increase of HIV infections. Alain Origer, Luxembourg <p>International updates</p> <ul style="list-style-type: none"> • European Commission: new EU Joint Action on HIV — Matthias Schuppe, DG Santé (in video conference) • WHO global health sector strategies — Antons Mozalevskis, WHO Europe 		
11.00	Coffee break		
11.30	<p>Parallel sessions on technical issues</p> <table border="0"> <tr> <td style="vertical-align: top;"> <p>Parallel session A. TDI data: consistencies and inconsistencies with DRID data Chairs: Linda Montanari and Magdalena Rosinska Discussant: Julian Vicente</p> <p>The purpose of this session is to discuss consistencies and inconsistencies between behavioural data collected through DRID and TDI sources, based on examples presented by the national experts and on an EMCDDA overview. The potential utility of these data as well as difficulties for cross-checking and increasing coherence between the different sources will be discussed.</p> <p>Behavioural data in the TDI and DRID data collection in Greece — Anastasios Fotiou, Greece</p> <p>Information on infectious diseases in/from registers on treatment and services for DUs in the Czech Republic — Barbara Janikova, Czech Republic</p> <p>Behavioral Data in TDI and DRID Data Collection in Croatia — Marko Markus, Croatia</p> <p>TDI and DRID behavioural data: preliminary assessment of consistency of HIV and HCV testing data — Linda Montanari, EMCDDA</p> </td> <td style="vertical-align: top;"> <p>Parallel session B. Detecting and responding to new threats: NPS injection and other risks (Room CDS 107) Chairs: Michael Evans-Brown and Vivian Hope</p> <p>The purpose of this session is to discuss how we can detect new signals with our networks and activate appropriate responses more efficiently. This will be based on some national examples where new psychoactive substances in particular are causing concern regarding infections and where the prevention responses are challenged to adapt.</p> <p>The impact of and responses to injecting NPS in South Wales — Josephine Smith, Wales, UK</p> <p>Impact of increasing NPS injecting combined with weakening responses: infections and risk behaviours — Anna Tarján, Hungary</p> <p>Rapid updates</p> <ul style="list-style-type: none"> • New HIV cases possibly related to mephedrone injection? — Margaret Curtin, Ireland • Acetylfentanyl deaths/harm reported in the UK — Michael Evans-Brown, EMCDDA </td> </tr> </table>	<p>Parallel session A. TDI data: consistencies and inconsistencies with DRID data Chairs: Linda Montanari and Magdalena Rosinska Discussant: Julian Vicente</p> <p>The purpose of this session is to discuss consistencies and inconsistencies between behavioural data collected through DRID and TDI sources, based on examples presented by the national experts and on an EMCDDA overview. The potential utility of these data as well as difficulties for cross-checking and increasing coherence between the different sources will be discussed.</p> <p>Behavioural data in the TDI and DRID data collection in Greece — Anastasios Fotiou, Greece</p> <p>Information on infectious diseases in/from registers on treatment and services for DUs in the Czech Republic — Barbara Janikova, Czech Republic</p> <p>Behavioral Data in TDI and DRID Data Collection in Croatia — Marko Markus, Croatia</p> <p>TDI and DRID behavioural data: preliminary assessment of consistency of HIV and HCV testing data — Linda Montanari, EMCDDA</p>	<p>Parallel session B. Detecting and responding to new threats: NPS injection and other risks (Room CDS 107) Chairs: Michael Evans-Brown and Vivian Hope</p> <p>The purpose of this session is to discuss how we can detect new signals with our networks and activate appropriate responses more efficiently. This will be based on some national examples where new psychoactive substances in particular are causing concern regarding infections and where the prevention responses are challenged to adapt.</p> <p>The impact of and responses to injecting NPS in South Wales — Josephine Smith, Wales, UK</p> <p>Impact of increasing NPS injecting combined with weakening responses: infections and risk behaviours — Anna Tarján, Hungary</p> <p>Rapid updates</p> <ul style="list-style-type: none"> • New HIV cases possibly related to mephedrone injection? — Margaret Curtin, Ireland • Acetylfentanyl deaths/harm reported in the UK — Michael Evans-Brown, EMCDDA
<p>Parallel session A. TDI data: consistencies and inconsistencies with DRID data Chairs: Linda Montanari and Magdalena Rosinska Discussant: Julian Vicente</p> <p>The purpose of this session is to discuss consistencies and inconsistencies between behavioural data collected through DRID and TDI sources, based on examples presented by the national experts and on an EMCDDA overview. The potential utility of these data as well as difficulties for cross-checking and increasing coherence between the different sources will be discussed.</p> <p>Behavioural data in the TDI and DRID data collection in Greece — Anastasios Fotiou, Greece</p> <p>Information on infectious diseases in/from registers on treatment and services for DUs in the Czech Republic — Barbara Janikova, Czech Republic</p> <p>Behavioral Data in TDI and DRID Data Collection in Croatia — Marko Markus, Croatia</p> <p>TDI and DRID behavioural data: preliminary assessment of consistency of HIV and HCV testing data — Linda Montanari, EMCDDA</p>	<p>Parallel session B. Detecting and responding to new threats: NPS injection and other risks (Room CDS 107) Chairs: Michael Evans-Brown and Vivian Hope</p> <p>The purpose of this session is to discuss how we can detect new signals with our networks and activate appropriate responses more efficiently. This will be based on some national examples where new psychoactive substances in particular are causing concern regarding infections and where the prevention responses are challenged to adapt.</p> <p>The impact of and responses to injecting NPS in South Wales — Josephine Smith, Wales, UK</p> <p>Impact of increasing NPS injecting combined with weakening responses: infections and risk behaviours — Anna Tarján, Hungary</p> <p>Rapid updates</p> <ul style="list-style-type: none"> • New HIV cases possibly related to mephedrone injection? — Margaret Curtin, Ireland • Acetylfentanyl deaths/harm reported in the UK — Michael Evans-Brown, EMCDDA 		
13.00	Lunch		

14.00	Parallel sessions
	<div style="display: flex; justify-content: space-between;"> <div style="width: 48%;"> <p>Parallel session C. HIV risk assessment updates Chairs: Dagmar Hedrich and Henrikki Brummer-Korvenkontio</p> <p>The purpose of this session is to have an update on trends in HIV infection among PWID and on indicators of infection risk and prevention. The session targets countries which had recent outbreaks, as well as those where risk or prevention indicators point to potential risk of transmission of infections among PWID.</p> <p>Prevalence of HIV and risk behaviours among PWID: an update, using data from cross-sectional study among PWID, conducted in Narva, 2014 — Maris Salekešin, Estonia</p> <p>Update on DRID among PWID: focus on recent institutional response — Lavinus Sava, Romania</p> <p>Update on risk of drug-related infections among PWID: results from a new prevalence study among PWID — Evelina Venckevic, Lithuania</p> <p>Harm reduction: who is responsible? The case of the syringe exchange programme in Israel — Daniel Chemtob, Israel</p> </div> <div style="width: 48%;"> <p>Parallel session D. Outbreaks: botulism and others (Room CDS 107) Chairs: Lucas Wiessing and Hans Blystad Discussant: Gregor Burkhart</p> <p>The purpose of this session is to review the recent outbreaks (botulism outbreaks; injection-related harm) in terms of time, place and persons (age, gender, pattern of drug use, global health status and psychosocial situation). The session will be an opportunity for all experts to discuss what is the role and added value of the DRID network in outbreak warning and control, and provide an opportunity to share and discuss outbreak-related procedures and other material used at national level</p> <p>Update on the cluster of wound botulism and discussion around diagnosis availability — Hans Blystad and Astrid Lovlie, Norway</p> <p>An outbreak of botulism associated with people who use drugs in Scotland — Gillian Penrice, United Kingdom</p> <p>Information/prevention targeted at drug users and professionals (Rapid updates and discussion)</p> <ul style="list-style-type: none"> • Vivian Hope, United Kingdom • Ruth Zimmerman, Germany <p>Rapid update:</p> <ul style="list-style-type: none"> • Injection in risky body parts and injection abscesses: epidemiology — Karin de Ridder, Belgium • Not in the vein: 'missed hits', subcutaneous and intramuscular injections among people who inject psychoactive drugs in Bristol, UK — Vivian Hope, United Kingdom </div> </div>
15.45	Coffee break
16.15	<p>Plenary session 2 The health of prisoners: a focus on infectious diseases Chairs: Linda Montanari and Eamonn O'Moore, WHO Collaborating Centre (in video conference) Discussant: Ruth Zimmerman</p> <p>The purpose of this session is to discuss available data on DRID (situation and responses) in prisons in European countries, to present an overview of the situation of health conditions and more specifically infectious diseases in prison, to identify the prisoners' main needs and update on on-going initiatives.</p> <p>Drug prevalence in prisons of Latvia in 2014 — Irina Lucenko, Latvia</p> <p>Infectious diseases in Spanish prisons — Elena Alvarez, Spain</p> <p>Prevalence of drug-use and BBV among the Irish prison population — Margaret Curtin, Ireland</p> <p>Health without barriers — Roberto Monarca, European Federation for Prison Health</p> <p>Monitoring harm reduction implementation in European prisons: public health and human rights approaches — Cinzia Brentari, Harm Reduction International</p>
18.00	Cocktail

Tuesday, 16 June 2015	
09.15	<p>Plenary session 3</p> <p>Scaling up responses to hepatitis C infection in Europe: what is next needed?</p> <p>Chairs: Isabelle Giraudon and Martin Busch</p> <p>Against the background of the WHO Europe's work on HCV and of modelling work on HCV treatment, this session will review and discuss European and national data on testing and prevalence, as well as access to and prices and coverage of HCV treatment.</p> <p>Hepatitis C in the WHO European Region — Antons Mozalevskis, WHO Europe</p> <p>HCV treatment and prevention: what is the impact of current treatment rates in selected sites in Europe? — Hannah Woodall, United Kingdom</p> <p>'Break Through' project on hepatitis C in addiction care: a care path from screening to treatment and aftercare for HCV-positive drug users — Esther Croes, the Netherlands</p> <p>Rapid updates</p> <ul style="list-style-type: none"> • Prices of the new generation of HCV medicines: survey among national focal points — Claudia Costa Storti, EMCDDA • Regulation of expenses for hepatitis C treatment in France — Anne-Claire Brisacier, France • Factors associated with undiagnosed hepatitis C infection among PWID: missed opportunities for diagnostic testing — Vivian Hope, United Kingdom
11.00	Coffee break
11.30	<p>Plenary session 4</p> <p>Relevance and perspective of DRID for the future: multi-indicator threat assessments, European and national strategic planning</p> <p>Chairs: Roland Simon and Julian Vicente</p> <p>The purpose of this session is to discuss the role of the DRID as part of the EMCDDA multi-indicator system for assessing emerging drug trends and threats. The session will start with a brief overview of the work planned in the strategic area of early warning systems and threat assessment (3-year strategy and work programme 2016–18, under preparation). It will focus in particular on identifying the potential and resources of the DRID expert platform. Short inputs from a panel of national experts will echo some of the highlights of the two-day meeting and open the floor for a plenary discussion.</p> <p>Panel contributions + plenary discussion + EMCDDA quick wrap-up</p> <p>Panelists:</p> <ul style="list-style-type: none"> • Martin Busch, Austria • Maris Salekešin, Estonia • Ruth Zimmermann, Germany • Elena Alvarez, Spain, • Vivian Hope, United Kingdom • Hans Blystad, Norway
13.00	End of the meeting